PFE - Pfizer Inc

NYSE * Health Care * Pharmaceuticals

$27.65

+$0.55 (+2.03%)

About Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PFE Key Statistics

Market Cap

$157.21B

P/E Ratio

20.33

P/B Ratio

1.66

EPS

$1.36

Dividend Yield

0.06%

Revenue Growth

-0.0%

Profit Margin

0.1%

Employees

81,000

How PFE Compares to Peers

PFE has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued
PFE has the highest profit margins in Pharmaceuticals
PFE is the smallest among peers, which may offer higher growth potential

P/E Rank

#1

of 2

Margin Rank

#1

of 2

Growth Rank

#2

of 2

Size Rank

#2

of 2

CompanyP/EGrowthCompare
PFE20.3-0%-
AMZN29.30%vs AMZN

Pfizer Inc Company Information

Headquarters
New York; U.S.A
Website
www.pfizer.com
Sector
Health Care
Industry
Pharmaceuticals
Data Updated:
Ready to invest in PFE?

Commission-free trading available. Affiliate links.

PFE Lician Score

14% confidence
6.0/10
Good

PFE has a Lician Score of 6/10 (Good). Strengths: Growth.

value

5.0

growth

8.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates PFEacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

PFE Financial Snowflake

5-axis analysis across key investment dimensions

5.6/10

Neutral

35810Value5.0Growth8.0Quality5.0Momentum5.0Safety5.05.6/10
5.0

Value

8.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for PFE